Zacks Research Has Pessimistic View of FMS Q4 Earnings

Fresenius Medical Care AG (NYSE:FMS - Free Report) - Equities research analysts at Zacks Research decreased their Q4 2024 earnings estimates for shares of Fresenius Medical Care in a research note issued on Monday, December 30th. Zacks Research analyst I. Bandyopadhyay now forecasts that the company will post earnings per share of $0.38 for the quarter, down from their prior forecast of $0.39. The consensus estimate for Fresenius Medical Care's current full-year earnings is $1.55 per share. Zacks Research also issued estimates for Fresenius Medical Care's Q1 2025 earnings at $0.39 EPS, Q2 2025 earnings at $0.42 EPS, Q3 2025 earnings at $0.53 EPS, Q4 2025 earnings at $0.54 EPS, FY2025 earnings at $1.87 EPS, Q1 2026 earnings at $0.46 EPS, Q2 2026 earnings at $0.47 EPS, Q3 2026 earnings at $0.59 EPS and FY2026 earnings at $2.13 EPS.

A number of other research firms have also commented on FMS. Truist Financial upped their price target on Fresenius Medical Care from $22.00 to $23.00 and gave the company a "hold" rating in a research report on Monday, October 7th. Berenberg Bank started coverage on Fresenius Medical Care in a report on Wednesday, November 6th. They set a "buy" rating and a $25.60 target price for the company. Bank of America upgraded shares of Fresenius Medical Care from an "underperform" rating to a "neutral" rating in a report on Monday, December 2nd. Finally, StockNews.com initiated coverage on shares of Fresenius Medical Care in a report on Thursday, November 28th. They issued a "strong-buy" rating for the company. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $24.30.

Fresenius Medical Care Trading Down 0.3 %

Shares of Fresenius Medical Care stock traded down $0.07 during trading on Wednesday, reaching $22.64. 83,757 shares of the stock were exchanged, compared to its average volume of 353,043. The company has a quick ratio of 1.02, a current ratio of 1.37 and a debt-to-equity ratio of 0.42. The firm has a market cap of $13.29 billion, a price-to-earnings ratio of 18.71, a price-to-earnings-growth ratio of 0.96 and a beta of 0.93. Fresenius Medical Care has a 1 year low of $17.93 and a 1 year high of $24.31. The stock's fifty day moving average is $22.19 and its 200 day moving average is $20.63.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Allworth Financial LP boosted its stake in Fresenius Medical Care by 53.1% during the third quarter. Allworth Financial LP now owns 1,675 shares of the company's stock worth $36,000 after acquiring an additional 581 shares in the last quarter. Mercer Global Advisors Inc. ADV boosted its position in shares of Fresenius Medical Care by 4.5% in the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 14,581 shares of the company's stock worth $278,000 after purchasing an additional 624 shares in the last quarter. Signaturefd LLC grew its stake in shares of Fresenius Medical Care by 8.4% in the 2nd quarter. Signaturefd LLC now owns 8,713 shares of the company's stock worth $166,000 after buying an additional 672 shares during the last quarter. MML Investors Services LLC increased its position in Fresenius Medical Care by 5.3% during the 3rd quarter. MML Investors Services LLC now owns 15,019 shares of the company's stock valued at $320,000 after buying an additional 753 shares in the last quarter. Finally, Ritholtz Wealth Management raised its stake in Fresenius Medical Care by 2.5% during the second quarter. Ritholtz Wealth Management now owns 36,901 shares of the company's stock valued at $704,000 after buying an additional 895 shares during the last quarter. Hedge funds and other institutional investors own 8.37% of the company's stock.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.